The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages E27-E38

  Xie, Ning ^a   Cheng, Helen ^a   Lin, Dong ^a   Liu, Liangliang ^a   Yang, Ou ^a   Jia, Li ^b   Fazli, Ladan ^a   Gleave, Martin E ^a   Wang, Yuzhuo ^a   Rennie, Paul ^a   Dong, Xuesen ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Brigham and Womens' Hospital   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen receptor; Glucocorticoid receptor; Prostate tumor

Indexed keywords

ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; PROSTATE SPECIFIC ANTIGEN; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN RESPONSIVE ELEMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; DNA STRUCTURE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; CANCER TRANSPLANTATION; DNA RESPONSIVE ELEMENT; GENETICS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICE, NUDE; MICE, SCID; NEOADJUVANT THERAPY; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84918507031     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29147     Document Type: Article

References (37)

1. Gleave M, Goldenberg SL, Bruchovsky N, et al. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience. Prostate Cancer Prostatic Dis 1998;1: 289-96
2. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29:3651-8
3. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012;24:251-7
4. Snoek R, Cheng H, Margiotti K, et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of wellestablished, castration-resistant prostate tumors. Clin Cancer Res 2009;15:39-47
5. Cheng H, Snoek R, Ghaidi F, et al. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006;66: 10613-20
6. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012;367:1187-97
8. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138:245-56
9. Wright AP, Zilliacus J, McEwan IJ, et al. Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 1993;47(1-6):11-19
10. Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 2013;73:1570-80
11. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309-22
12. Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Hormones Cancer 2014;5:72-89
13. Montgomery B, Cheng HH, Drechsler J, et al. Glucocorticoids and prostate cancer treatment: Friend or foe? Asian J Androl 2014;16:354-8
14. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-7
15. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormonerefractory metastatic prostate carcinoma. Cancer 1995;76:96-100
16. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13
17. Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase. Cancer Cell 2011;20:457-71
18. Zhao JC, Yu J, Runkle C, et al. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 2012;22: 322-31
19. Qi J, Tripathi M, Mishra R, et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013;23: 332-46
20. Wang Q, Tiffen J, Bailey CG, et al. Targeting amino acid transport in metastatic castrationresistant prostate cancer: Effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 2013;105:1463-73
21. Yu Y, Liu L, Xie N, et al. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metabolism 2013;98: 2887-96
22. Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014;74:1272-83
23. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012;227:286-97
24. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Dis 2011;1:487-95
25. Yu Y, Lee JS, Xie N, et al. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PloS One 2014;9:e92714
26. Liu LL, Xie N, Sun S, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2014;33:3140-50
27. Decker KF, Zheng D, He Y, et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012;40:10765-79
28. Rennie PS, Bruchovsky N, Leco KJ, et al. Characterization of two cis-Acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7:23-36
29. Read JT, Cheng H, Hendy SC, et al. Receptor- DNA interactions: EMSA and footprinting. Methods Mol Biol 2009;505:97-122
30. Xie N, Liu L, Li Y, et al. Expression and function of myometrial PSF suggest a role in progesterone withdrawal and the initiation of labor. Mol Endocrinol 2012;26:1370-9
31. Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-46
32. Li Z, Chen Y, Cao D, et al. Glucocorticoid upregulates transforming growth factor-beta (TGFbeta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 2006;147:5259-67
33. Yemelyanov A, Czwornog J, Chebotaev D, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007;26:1885-96
34. Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006;12: 3003-3009
35. Welsh TH, Jr, Bambino TH, Hsueh AJ. Mechanism of glucocorticoid-induced suppression of testicular androgen biosynthesis in vitro. Biol Reprod 1982;27:1138-46
36. Qin J, Liu X, Laffin B, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012;10:556-69
37. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27:380-92.